BeiGene BGB-3111-212 An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

Clinical Trial Grant

Duke Scholars

Principal Investigator Matthew Stuart McKinney Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

June 26, 2018

End Date

July 14, 2023

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

June 26, 2018

End Date

July 14, 2023